Sitting Pretty | GenomeWeb

Sitting Pretty


As genomics stocks bottom out, here’s who’s still on top

$7.1M William Rich, Ciphergen, CEO

$63.1M Mark Chandler, Luminex, CEO

$213.3M Lyle Turner, Invitrogen, CEO

$2.7M Mark Boguski, Rosetta Inpharmatics, Sr. VP of R&D

$6.9M William Matthews, Deltagen, CEO

$4.9M Mark Gessler, Gene Logic, CEO

$1.8M Stuart Collinson, Aurora Biosciences, CEO

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.